112 related articles for article (PubMed ID: 28971610)
21. Pharmacokinetic Interaction Between Imatinib and Metformin in Rats.
Fan N; Du L; Guo T; Liu M; Chen X
Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):171-179. PubMed ID: 38141154
[TBL] [Abstract][Full Text] [Related]
22. Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug-Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective.
Choi HJ; Madari S; Huang F
Clin Pharmacokinet; 2024 Jun; ():. PubMed ID: 38867094
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Systemic and Brain Pharmacokinetic Parameters for Repurposing Metformin Using Intravenous Bolus Administration.
Sharma S; Zhang Y; Patel D; Akter KA; Bagchi S; Sifat AE; Nozohouri E; Ahn Y; Karamyan VT; Bickel U; Abbruscato TJ
J Pharmacol Exp Ther; 2024 May; ():. PubMed ID: 38777603
[TBL] [Abstract][Full Text] [Related]
24. Metformin-Cimetidine Drug Interaction and Risk of Lactic Acidosis in Renal Failure: A Pharmacovigilance-Pharmacokinetic Appraisal.
Xie W; Li J; Kong C; Luo W; Zheng J; Zhou Y
Diabetes Care; 2024 Jan; 47(1):144-150. PubMed ID: 37948503
[TBL] [Abstract][Full Text] [Related]
25. Why Should Metformin Not Be Given in Advanced Kidney Disease? Potential Leads from Computer Simulations.
Kokic Males V; Požar M
ACS Omega; 2021 Jun; 6(23):15382-15391. PubMed ID: 34151116
[TBL] [Abstract][Full Text] [Related]
26. Coordination chemistry suggests that independently observed benefits of metformin and Zn
Lockwood TD
Biometals; 2024 Apr; ():. PubMed ID: 38578560
[TBL] [Abstract][Full Text] [Related]
27. Elucidation of
Miyake T; Mizuno T; Takehara I; Mochizuki T; Kimura M; Matsuki S; Irie S; Watanabe N; Kato Y; Ieiri I; Maeda K; Ando O; Kusuhara H
Drug Metab Dispos; 2019 Nov; 47(11):1270-1280. PubMed ID: 31511257
[TBL] [Abstract][Full Text] [Related]
28. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
29. Novel method of measurement of in vitro drug uptake in OATP1B3 overexpressing cells in the presence of dextran.
Kowal-Chwast A; Gabor-Worwa E; Gaud N; Gogola D; Piątek A; Zarębski A; Littlewood P; Smoluch M; Brzózka K; Kuś K
Pharmacol Rep; 2024 Apr; 76(2):400-415. PubMed ID: 38530582
[TBL] [Abstract][Full Text] [Related]
30. Imeglimin: A Clinical Pharmacology Review.
Chevalier C; Fouqueray P; Bolze S
Clin Pharmacokinet; 2023 Oct; 62(10):1393-1411. PubMed ID: 37713097
[TBL] [Abstract][Full Text] [Related]
31. Hfq Regulates Efflux Pump Expression and Purine Metabolic Pathway to Increase Trimethoprim Resistance in
Wang D; Li H; Ma X; Tang Y; Tang H; Huang D; Lin M; Liu Z
Front Microbiol; 2021; 12():742114. PubMed ID: 34899630
[No Abstract] [Full Text] [Related]
32. Substrate-Dependent
Lefèvre CR; Le Vée M; Gaubert S; Jouan E; Bruyere A; Moreau C; Fardel O
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884730
[TBL] [Abstract][Full Text] [Related]
33. A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.
Yang Y; Zhang Z; Li P; Kong W; Liu X; Liu L
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34064886
[TBL] [Abstract][Full Text] [Related]
34. Organic Cation Transporter 1 an Intestinal Uptake Transporter: Fact or Fiction?
Wenzel C; Drozdzik M; Oswald S
Front Pharmacol; 2021; 12():648388. PubMed ID: 33935750
[TBL] [Abstract][Full Text] [Related]
35. A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug-Drug-Gene Interaction Predictions.
Türk D; Hanke N; Lehr T
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33182761
[TBL] [Abstract][Full Text] [Related]
36. Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury.
Al-Naimi MS; Rasheed HA; Hussien NR; Al-Kuraishy HM; Al-Gareeb AI
J Adv Pharm Technol Res; 2019; 10(3):95-99. PubMed ID: 31334089
[TBL] [Abstract][Full Text] [Related]
37. Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine.
Nishiyama K; Toshimoto K; Lee W; Ishiguro N; Bister B; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):396-406. PubMed ID: 30821133
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
Elsby R; Chidlaw S; Outteridge S; Pickering S; Radcliffe A; Sullivan R; Jones H; Butler P
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971610
[TBL] [Abstract][Full Text] [Related]
39. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
40. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
